financetom
Business
financetom
/
Business
/
Verisign Contract to Manage Internet Domains Challenged by US Lawmakers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Verisign Contract to Manage Internet Domains Challenged by US Lawmakers
Jul 25, 2024 11:39 AM

02:17 PM EDT, 07/25/2024 (MT Newswires) -- Verisign's ( VRSN ) long-held contract with a federal agency to manage internet domains is being challenged by members of the US House Committee on Energy and Commerce.

The members want the National Telecommunications and Information Administration to "reassess" many of the terms of its contract with Verisign ( VRSN ) to manage internet domain names and registries prior to its scheduled renewal later this year.

Verisign ( VRSN ) has operated the .com and .net domain registries since 2006 under a contract with NTIA. The current contract expires Nov. 30. In their letter to NTIA Administrator Alan Davidson, the three lawmakers asked whether the contract should instead be put up for competitive bids instead of automatically renewing every four years at the company's option.

The lawmakers, all Republicans, also want to re-examine provisions of the contract. The company has increased the price of registering or renewing a .com or .net domain name by as much as 7% per year.

"Some have argued that Verisign ( VRSN ) enjoys considerable profit margins from managing the registry, charging far more than it costs to operate it," according to the letter signed by committee chair Cathy McMorris Rodgers (R-Washington) and two subcommittee chairmen. They also asked Davidson to provide details of any negotiations with Verisign ( VRSN ) as well as any input from other federal authorities or the public about the contract process before Aug. 8.

Verisign ( VRSN ) did not immediately respond to a message from MT Newswires seeking comment.

Price: 176.70, Change: +1.73, Percent Change: +0.99

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Shift4 Payments to Buy Givex in All Cash Deal Valued at C$200 Million
Shift4 Payments to Buy Givex in All Cash Deal Valued at C$200 Million
Aug 26, 2024
08:58 AM EDT, 08/26/2024 (MT Newswires) -- Givex ( GIVXF ) -- with integrated end-to-end management solutions that provide Gift Cards, GivexPOS, Loyalty Programs -- on Monday agreed to be acquired by Shift4 Payments in an all cash deal valued at about C$200 million on a fully diluted, in-the-money, treasury method basis. Under the terms of the agreement, Givex (...
KKR Closes Acquisition of Varsity Brands From Bain, Charlesbank
KKR Closes Acquisition of Varsity Brands From Bain, Charlesbank
Aug 26, 2024
08:57 AM EDT, 08/26/2024 (MT Newswires) -- KKR (KKR) said Monday it has completed its acquisition of Varsity Brands from Bain Capital and Charlesbank. Financial terms of the transaction were not disclosed. KKR's investment is being made through its North America Fund XIII. The investment firm said it will launch an equity ownership program for employees of the sportswear and...
Trudeau says Canada to impose 100% tariff on Chinese EVs
Trudeau says Canada to impose 100% tariff on Chinese EVs
Aug 26, 2024
OTTAWA (Reuters) - Prime Minister Justin Trudeau said on Monday that Canada will impose a 100% tariff on the import of Chinese electric vehicles. Ottawa will also impose a 25% tariff on imported steel and aluminum from China, Trudeau told reporters in Halifax, Nova Scotia. The tariffs come a little over a month after Ottawa opened a 30-day public consultation...
Rhythm Pharmaceuticals Says US FDA Accepts its Supplemental New Drug Application for Imcivree
Rhythm Pharmaceuticals Says US FDA Accepts its Supplemental New Drug Application for Imcivree
Aug 26, 2024
08:57 AM EDT, 08/26/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Monday the US Food and Drug Administration has accepted the company's supplemental New Drug Application for Imcivree to treat obesity due to Bardet-Biedl syndrome or pro-opiomelanocortin in children as young as 2 years old. The company said the submission is based on data from a phase 3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved